Abstract: This invention provides a safe and highly stable peritoneal dialysate, which causes neither peritoneal membrane disorders nor peritoneal sclerosis associated with frequently repeated peritoneal dialysis treatment, which can protect residual renal functions in chronic renal failure, which inhibits the progress of renal damage over a long period of time, and which enables peritoneal dialysis treatment of diabetic patients. This peritoneal dialysate contains 0.05 to 3.5 w/v % of taurine and 0.1 to 6.5 w/v % of trehalose as osmotic agents and has a pH value adjusted between 6.5-7.5.

Abstract: The present invention aims at preventing or retarding a transition to hemodialysis treatment in kidney failure or decreasing the number of implementation of the hemodialysis therapy and preventing or lessening occurrence of accompanying hyperammonemia in hepatic insufficiency. To accomplish the purposes described above, the pathological improvement food of the invention is featured by being composed chiefly of indigestible polysaccharides and having restricted addition of protein components. Energy produced by exploiting the indigestible polysaccharides contributes to fungal protein synthesis using, as a N-source, urea or ammonia secretion into the intestine and excretion of proliferated bacteria with feces, so that nitrogen-containing low-molecular substances in the blood can be decreased, thereby to improve disorder of the kidney and liver.

Abstract: In this invention, injection kit is to provide. The kit is made of multiple layered flexible plastic bag formed cylindrically (soft bag), and is separated into 2˜4 compartments by one or plural welded partition easy-to-peel seal. The first compartment has a welded nozzle-like outlet of the injection solution and contains a solid medicine. The rearmost compartment (the last compartment of this kit) contains a solvent to dissolve the solid medicine. The remaining one or two mid-compartment contains a solid medicine and/or its solvent. The welded nozzle-like outlet of the first compartment is welded with a metallic injection needle, which is covered by a plastic protective cap before it is used.

Abstract: The present invention relates to an amino acid derivative represented by the formula ##STR1## wherein R.sub.1 and R.sub.2 represent hydroxyl, alkyloxy, aryloxy, arylkyloxy, alkyl, aryl, or aralkyl; R.sub.3, R.sub.5, R.sub.8 and R.sub.11 are hydrogen or alkyl; R.sub.4, R.sub.7 and R.sub.10 are hydrogen, or substituted or unsubstituted alkyl, aryl or aralkyl; R.sub.6 and R.sub.9 are hydrogen, alkyl, aryl, or aralkyl; R.sub.12 is hydroxyl, alkyloxy, aryloxy, aralkyloxy, amino, mono- or di-alkyl-, aryl- or aralkyl amino; and R.sub.6 and R.sub.7 combined together, and R.sub.9 and R.sub.10 combined together independently may form a substituted or unsubstituted alkylene bridge. The present invention also relates to a method of preparing said amino acid derivatives, and to anti-hypertensive drugs containing them.

Abstract: N-terminal phosphorus dipeptides having antihypertensive properties are disclosed.

Abstract: The present invention relates to an amino acid derivative represented by the formula ##STR1## wherein R.sub.1 and R.sub.2 represent hydroxyl, alkyloxy, aryloxy, arylkyloxy, alkyl, aryl, or aralkyl; R.sub.3, R.sub.5, R.sub.8 and R.sub.11 are hydrogen or alkyl; R.sub.4, R.sub.7 and R.sub.10 are hydrogen, or substituted or unsubstituted alkyl, aryl or aralkyl; R.sub.6 and R.sub.9 are hydrogen, alkyl, aryl, or aralkyl; R.sub.12 is hydroxyl, alkyloxy, aryloxy, aralkyloxy, amino, mono- or di-alkyl-, aryl- or aralkyl amino; and R.sub.6 and R.sub.7 combined together, and R.sub.9 and R.sub.10 combined together independently may form a substituted or unsubstituted alkylene bridge. The present invention also relates to a method of preparing said amino acid derivatives, and to anti-hypertensive drugs containing them.

Abstract: The glucans and glucan derivatives which inhibit the growth of sarcoma 180 in mice are only sparingly soluble in water, and their aqueous solutions are unstable. In the presence of 0.1 to 1.0 g/dl water soluble dextran, hydroxyethyl starch, carboxymethyl cellulose, or polyethylene glycol, they form relatively concentrated and stable solutions, particularly in the presence of hexoses, pentoses or sugar alcohols having 5 or 6 carbon atoms.

Abstract: Method for the isolation of urokinase from human urine in which the urokinase is adsorbed and thereafter eluted with aqueous cation surfactant mixture. Novel carboxyalkyl cellulose is utilized as a preferred adsorbent.

Abstract: Immobilized biologically active proteins such as enzymes having high activity and stability are prepared by covalent bonding of the biologically active protein to an azide derivative of a polypeptide such as polymethylglutamate of which at least one carboxyl group in a side chain is converted to a carboxyl azide group.

Abstract: The activity of urokinase in aqueous solution is stabilized and enhanced by addition of water soluble amines selected from the group consisting of amino sugars, amino acids and cationic surfactants.